12 results on '"Mayer, Christopher"'
Search Results
2. Electrocardiographic parameters of left ventricular hypertrophy and prediction of mortality in hemodialysis patients
- Author
-
Braunisch, Matthias C., Gundel, Peter, Werfel, Stanislas, Mayer, Christopher C., Bauer, Axel, Haller, Bernhard, Günthner, Roman, Lorenz, Georg, Angermann, Susanne, Matschkal, Julia, Schaller, Carolin, Holzmann-Littig, Christopher, Kemmner, Stephan, Mann, Johannes, Krieter, Axel, Renders, Lutz, Wassertheurer, Siegfried, Schmidt, Georg, Heemann, Uwe, Malik, Marek, and Schmaderer, Christoph
- Published
- 2022
- Full Text
- View/download PDF
3. Bioimpedance-derived euvolemic weight varies in hemodialysis patients—challenging the fixed target weight concept.
- Author
-
Waller, Maximilian, Krenn, Simon, Mussnig, Sebastian, Schmiedecker, Michael, Niknam-Saeidi, Janosch, Mayer, Christopher C, Wabel, Peter, Schneditz, Daniel, Chazot, Charles, and Hecking, Manfred
- Subjects
HEMODIALYSIS patients ,WEIGHT gain ,BODY mass index ,BODY composition ,BODY fluids ,PATIENT compliance - Abstract
This article challenges the concept of a fixed target weight in hemodialysis (HD) patients. The authors conducted a study with 25 HD patients and used bioimpedance spectroscopy (BIS) measurements to analyze fluid status and body composition. They found that the patients' euvolemic body weight varied longitudinally, indicating that target weight might need to be adjusted in individual HD patients. The authors suggest that a soft target weight prescription could be more physiological and potentially reduce complications such as intradialytic hypotension. However, there are limitations to the study, including a small sample size and non-standardized recording of pre-dialysis weight. [Extracted from the article]
- Published
- 2024
- Full Text
- View/download PDF
4. Chronic kidney disease and neurological disorders: are uraemic toxins the missing piece of the puzzle?
- Author
-
Liabeuf, Sophie, Pepin, Marion, Franssen, Casper, Viggiano, Davide, Carriazo, Sol, Gansevoort, Ron, Gesualdo, Loreto, Hafez, Gaye, Malyszko, Jolanta, Mayer, Christopher, Nitsch, Dorothea, Ortiz, Alberto, Pešić, Vesna, Wiecek, Andrzej, Massy, Ziad, Capasso, Giovambattista, Andrade, Alexandre, Bachmann, Maie, Bumblyte, Inga, Covic, Adrian Constantin, Delgado, Pilar, Endlich, Nicole, Engvig, Andreas, Fouque, Denis, Frische, Sebastian, Garneata, Liliana, Giannakou, Konstantinos, Goumenos, Dimitrios, Kartal, Ayşe Tuğba, Mani, Laila-Yasmin, Marti, Hans-Peter, Nielsen, Rikke, Rroji, Merita, Sakkas, Giorgos, Spasovski, Goce, Stevens, Kate, Vazelov, Evgueniy, Zacharia, Lefteris, Ferreira, Ana Carina, Hoorn, Ewout, Figurek, Andreja, Unwin, Robert, Wagner, Carsten, Wanner, Christoph, BRUCHFELD, Annette, Fridolin, Ivo, Romeo, Maria José Soler, Barbieri, Michelangela, Batinić, Bojan, Carrasco, Laura, Martino, Gianvito, Raso, Francesco Mattace, Nistor, Ionut, Paolisso, Giuseppe, Rastenytė, Daiva, Stefan, Gabriel, Tedeschi, Gioacchino, Bikbov, Boris, Endlich, Karl Hans, Godefroy, Olivier, Chillon, Jean-Marc, Kossioni, Anastassia, Kurganaite, Justina, Perico, Norberto, Remuzzi, Giuseppe, Grodzicki, Tomasz, Trepiccione, Francesco, Zoccali, Carmine, Arici, Mustafa, Blankestijn, Peter, Eckardt, Kai-Uwe, Fliser, Danilo, Jiménez, Eugenio Gutiérrez, Konig, Maximilian, Rychlik, Ivan, Deleidi, Michela, REUSZ, George, Mécanismes physiopathologiques et conséquences des calcifications vasculaires - UR UPJV 7517 (MP3CV), Université de Picardie Jules Verne (UPJV)-CHU Amiens-Picardie, Hôpital Ambroise Paré [AP-HP], Groningen University Medical Centre, Department of Nephrology [Groningue, Pays-Bas], University Medical Center Groningen [Groningen] (UMCG), CeRTA, Liabeuf, S., Pepin, M., Franssen, C. F. M., Viggiano, D., Carriazo, S., Gansevoort, R. T., Gesualdo, L., Hafez, G., Malyszko, J., Mayer, C., Nitsch, D., Ortiz, A., Pesic, V., Wiecek, A., and Massy, Z. A.
- Subjects
medicine.medical_specialty ,CLINICAL-OUTCOMES ,HEMODIALYSIS ,Movement disorders ,030232 urology & nephrology ,RENAL DYSFUNCTION ,URIC-ACID ,Review ,03 medical and health sciences ,0302 clinical medicine ,PARKINSONS-DISEASE ,Diabetes mellitus ,Internal medicine ,Epidemiology ,medicine ,CKD ,INDOXYL SULFATE ,AcademicSubjects/MED00340 ,Stroke ,Depression (differential diagnoses) ,RISK ,Transplantation ,Kidney ,COMPLICATIONS ,business.industry ,cardiovascular ,medicine.disease ,COGNITIVE FUNCTION ,indoxyl sulphate ,stroke ,3. Good health ,medicine.anatomical_structure ,Clinical research ,Nephrology ,[SDV.SP.PHARMA]Life Sciences [q-bio]/Pharmaceutical sciences/Pharmacology ,[SDV.SPEE]Life Sciences [q-bio]/Santé publique et épidémiologie ,medicine.symptom ,business ,030217 neurology & neurosurgery ,Kidney disease ,uraemic toxins - Abstract
Chronic kidney disease (CKD) perturbs the crosstalk with others organs, with the interaction between the kidneys and the heart having been studied most intensively. However, a growing body of data indicates that there is an association between kidney dysfunction and disorders of the central nervous system. In epidemiological studies, CKD is associated with a high prevalence of neurological complications, such as cerebrovascular disorders, movement disorders, cognitive impairment and depression. Along with traditional cardiovascular risk factors (such as diabetes, inflammation, hypertension and dyslipidaemia), non-traditional risk factors related to kidney damage (such as uraemic toxins) may predispose patients with CKD to neurological disorders. There is increasing evidence to show that uraemic toxins, for example indoxyl sulphate, have a neurotoxic effect. A better understanding of factors responsible for the elevated prevalence of neurological disorders among patients with CKD might facilitate the development of novel treatments. Here, we review (i) the potential clinical impact of CKD on cerebrovascular and neurological complications, (ii) the mechanisms underlying the uraemic toxins’ putative action (based on pre-clinical and clinical research) and (iii) the potential impact of these findings on patient care., Graphical Abstract Graphical Abstract
- Published
- 2021
5. Ultrafiltration‐induced decrease in relative blood volume is larger in hemodialysis patients with low specific blood volume: Results from a dialysate bolus administration study.
- Author
-
Schmiedecker, Michael, Krenn, Simon, Waller, Maximilian, Paschen, Christopher, Mussnig, Sebastian, Niknam, Janosch, Wabel, Peter, Mayer, Christopher C., Hecking, Manfred, and Schneditz, Daniel
- Subjects
BLOOD volume ,HEMODIALYSIS patients ,BLOOD volume determination ,BODY mass index - Abstract
Introduction: Prescribing the ultrafiltration in hemodialysis patients remains challenging and might benefit from the information on absolute blood volume, estimated by intradialytic dialysate bolus administration. Here, we aimed at determining the relationship between absolute blood volume, normalized for body mass (specific blood volume, Vs), and ultrafiltration‐induced decrease in relative blood volume (∆RBV) as well as clinical parameters including body mass index (BMI). Methods: This retrospective analysis comprised 77 patients who had their dialysate bolus‐based absolute blood volume extracted routinely with an automated method. Patient‐specific characteristics and ∆RBV were analyzed as a function of Vs, dichotomizing the data above or below a previously proposed threshold of 65 ml/kg for Vs. Statistical methodology comprised descriptive analyses, two‐group comparisons, and correlation analyses. Findings: Median Vs was 68.6 ml/kg (54.9 ml/kg [Quartile 1], 83.4 ml/kg [Quartile 3]). Relative blood volume decreased by 6.3% (2.6%, 12.2%) over the entire hemodialysis session. Vs correlated inversely with BMI (rs = −0.688, p < 0.001). ∆RBV was 9.8% in the group of patients with Vs <65 ml/kg versus 6.0% in the group of patients with Vs ≥65 ml/kg (p = 0.024). The two groups did not differ significantly regarding their specific ultrafiltration volume, normalized for body mass, which amounted to 34.1 ml/kg and 36.0 ml/kg in both groups, respectively (p = 0.630). ∆RBV correlated inversely with Vs (rs = −0.299, p = 0.008). Discussion: The present study suggests that patients with higher BMI and lower Vs experience larger blood volume changes, despite similar ultrafiltration requirements. These results underline the clinical plausibility and importance of dialysate bolus‐based absolute blood volume determination in the assessment of target weight, especially in view of a previous study where intradialytic morbid events could be decreased when the target weight was adjusted, based on Vs. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
6. U-Shaped Association of the Heart Rate Variability Triangular Index and Mortality in Hemodialysis Patients With Atrial Fibrillation
- Author
-
Braunisch, Matthias C., Mayer, Christopher C., Werfel, Stanislas, Bauer, Axel, Haller, Bernhard, Lorenz, Georg, Günthner, Roman, Matschkal, Julia, Bachmann, Quirin, Thunich, Stephan, Schlegl, Michaela, Ludwig, Maximilian, Holzmann-Littig, Christopher, Assali, Tarek, Pachmann, Martin, Küchle, Claudius, Renders, Lutz, Wassertheurer, Siegfried, Müller, Alexander, Schmidt, Georg, Heemann, Uwe, Malik, Marek, and Schmaderer, Christoph
- Subjects
risk prediction ,hemodialysis ,cardiovascular mortality ,HRVi ,atrial fibrillation ,Cardiovascular Medicine ,Cardiology and Cardiovascular Medicine ,heart rate variability triangular index ,Original Research - Abstract
Background: Atrial fibrillation (AF) is common in hemodialysis patients and contributes to increased mortality. We aimed to examine heart rate variability triangular index (HRVI) in hemodialysis patients with AF as it has recently been reported to predict mortality in AF patients without kidney disease. Methods: A total of 88 patients on hemodialysis with a medical history of AF or newly diagnosed AF underwent 24-h electrocardiography recordings. The primary endpoint of cardiovascular mortality was recorded during a median follow up of 3.0 years. Risk prediction was assessed by Cox regression, both unadjusted and adjusted for the Charlson Comorbidity Index and the Cardiovascular Mortality Risk Score. Results: Median age was 76 years, median dialysis vintage was 27 months. Altogether, 22 and 44 patients died due to cardiovascular and non-cardiovascular causes. In 55% of patients AF was present during the recording. Kaplan-Meier plots of HRVI quartiles suggested a non-linear association between HRVI, cardiovascular, and all-cause mortality which was confirmed in non-linear Cox regression analysis. Adjusted linear Cox regression revealed a hazard ratio of 6.2 (95% CI: 2.1–17.7, p = 0.001) and 2.2 (95% CI: 1.3–3.8, p = 0.002) for the outer quartiles (combined first and fourth quartile) for cardiovascular and all-cause mortality, respectively. Patients in the first quartile were more likely to have sinus rhythm whereas patients in the fourth quartile were more likely to have AF. Conclusions: We found a U-shaped association between HRVI and mortality in hemodialysis AF patients. The results might contribute to risk stratification independent of known risk scores in hemodialysis AF patients.
- Published
- 2021
7. Cardiovascular Mortality Can Be Predicted by Heart Rate Turbulence in Hemodialysis Patients
- Author
-
Braunisch, Matthias C., Mayer, Christopher C., Bauer, Axel, Lorenz, Georg, Haller, Bernhard, Rizas, Konstantinos D., Hagmair, Stefan, von Stülpnagel, Lukas, Hamm, Wolfgang, Günthner, Roman, Angermann, Susanne, Matschkal, Julia, Kemmner, Stephan, Hasenau, Anna-Lena, Zöllinger, Isabel, Steubl, Dominik, Mann, Johannes F., Lehnert, Thomas, Scherf, Julia, Braun, Jürgen R., Moog, Philipp, Küchle, Claudius, Renders, Lutz, Malik, Marek, Schmidt, Georg, Wassertheurer, Siegfried, Heemann, Uwe, and Schmaderer, Christoph
- Subjects
hemodialysis ,cardiovascular mortality ,mortality risk prediction ,Medizinische Fakultät ,Physiology ,Physiology (medical) ,heart rate turbulence ,baroreflex ,ddc:610 ,Original Research - Abstract
Background Excess mortality in hemodialysis patients is mostly of cardiovascular origin. We examined the association of heart rate turbulence (HRT), a marker of baroreflex sensitivity, with cardiovascular mortality in hemodialysis patients. Methods A population of 290 prevalent hemodialysis patients was followed up for a median of 3 years. HRT categories 0 (both turbulence onset [TO] and slope [TS] normal), 1 (TO or TS abnormal), and 2 (both TO and TS abnormal) were obtained from 24 h Holter recordings. The primary end-point was cardiovascular mortality. Associations of HRT categories with the endpoints were analyzed by multivariable Cox regression models including HRT, age, albumin, and the improved Charlson Comorbidity Index for hemodialysis patients. Multivariable linear regression analysis identified factors associated with TO and TS. Results During the follow-up period, 20 patients died from cardiovascular causes. In patients with HRT categories 0, 1 and 2, cardiovascular mortality was 1, 10, and 22%, respectively. HRT category 2 showed the strongest independent association with cardiovascular mortality with a hazard ratio of 19.3 (95% confidence interval: 3.69–92.03; P < 0.001). Age, calcium phosphate product, and smoking status were associated with TO and TS. Diabetes mellitus and diastolic blood pressure were only associated with TS. Conclusion Independent of known risk factors, HRT assessment allows identification of hemodialysis patients with low, intermediate, and high risk of cardiovascular mortality. Future prospective studies are needed to translate risk prediction into risk reduction in hemodialysis patients.
- Published
- 2020
- Full Text
- View/download PDF
8. Comparison of 24-hour and Office Pulse Wave Velocity for Prediction of Mortality in Hemodialysis Patients.
- Author
-
Matschkal, Julia, Mayer, Christopher C., Sarafidis, Pantelis A., Lorenz, Georg, Braunisch, Matthias C., Guenthner, Roman, Angermann, Susanne, Steubl, Dominik, Kemmner, Stephan, Bachmann, Quirin, Hauser, Christine, Nerl, Louisa, Baumann, Marcus, Mann, Johannes F., Moog, Philipp, Kuechle, Claudius, Renders, Lutz, Heemann, Uwe, Wassertheurer, Siegfried, and Schmaderer, Christoph
- Subjects
HEMODIALYSIS patients ,CHRONIC kidney failure ,MORTALITY ,AMBULATORY blood pressure monitoring ,VELOCITY ,TREATMENT of chronic kidney failure ,CARDIOVASCULAR disease diagnosis ,COMPARATIVE studies ,HEMODIALYSIS ,LONGITUDINAL method ,RESEARCH methodology ,MEDICAL appointments ,MEDICAL cooperation ,PROGNOSIS ,RESEARCH ,RISK assessment ,EVALUATION research ,PREDICTIVE tests ,KAPLAN-Meier estimator - Abstract
Background: Mortality in hemodialysis patients still remains unacceptably high. Enhanced arterial stiffness is a known cardiovascular risk factor, and pulse wave velocity (PWV) has proven to be a valid parameter to quantify risk. Recent studies showed controversial results regarding the prognostic significance of PWV for mortality in hemodialysis patients, which may be due to methodological issues, such as assessment of PWV in the office setting (Office-PWV).Method: This study cohort contains patients from the "Risk stratification in end-stage renal disease - the ISAR study," a multicenter prospective longitudinal observatory cohort study. We examined and compared the predictive value of ambulatory 24-hour PWV (24 h-PWV) and Office-PWV on mortality in a total of 344 hemodialysis patients. The endpoints of the study were all-cause and cardiovascular mortality. Survival analysis included Kaplan-Meier estimates and Cox regression analysis.Results: During a follow-up of 36 months, a total of 89 patients died, 35 patients due to cardiovascular cause. Kaplan-Meier estimates for tertiles of 24 h-PWV and Office-PWV were similarly associated with mortality. In univariate Cox regression analysis, 24 h-PWV and Office-PWV were equivalent predictors for all-cause and cardiovascular mortality. After adjustment for common risk factors, only 24 h-PWV remained solely predictive for all-cause mortality (hazard ratio 2.51 [95% CI 1.31-4.81]; p = 0.004).Conclusions: Comparing both measurements, 24 h-PWV is an independent predictor for all-cause-mortality in hemodialysis patients beyond Office-PWV. [ABSTRACT FROM AUTHOR]- Published
- 2019
- Full Text
- View/download PDF
9. Acetate-free, citrate-acidified bicarbonate dialysis improves serum calcification propensity—a preliminary study.
- Author
-
Lorenz, Georg, Mayer, Christopher C, Bachmann, Quirin, Stryeck, Sarah, Braunisch, Matthias C, Haller, Bernhard, Carbajo-Lozoya, Javier, Schmidt, Alina, Witthauer, Simon, and Abuzahu, Jasmin
- Subjects
- *
CHRONIC kidney failure , *HEMODIALYSIS , *CALCIFICATION , *DISEASE prevalence , *CHRONIC disease treatment , *SERUM albumin , *HOMEOSTASIS - Abstract
Background A novel in vitro test (T50 test) assesses ex vivo serum calcification propensity and predicts mortality in chronic kidney disease and haemodialysis (HD) patients. For the latter, a time-dependent decline of T50 was shown to relate to mortality. Here we assessed whether a 3-month switch to acetate-free, citrate-acidified, standard bicarbonate HD (CiaHD) sustainably improves calcification propensity. Methods T50 values were assessed in paired midweek pre-dialysis sera collected before and 3 months after CiaHD in 78 prevalent European HD patients. In all, 44 were then switched back to acetate. Partial correlation was used to study associations of changing T50 and changing covariates. Linear mixed effect models were built to assess the association of CiaHD and covariates with changing T50. Results A significant intra-individual increase of serum calcification resilience was found after 3 months on CiaHD (206 ± 56 to 242 ± 56 min; P < 0.001), but not after switching back to acetate (252 ± 63 to 243 ± 64 min; n = 44; P = 0.29). CiaHD, Δ serum phosphate and Δ albumin but not Δ ionized calcium and magnesium were the strongest determinants of changing T50. Beneath T50, only serum albumin but not phosphate changed significantly during 3 months of CiaHD. Conclusion CiaHD dialysis favourably affected calcification propensity as measured by the T50 test. Whether this treatment, beyond established phosphate-directed treatments, has the potential to sustainably tip the balance towards a more anti-calcific serum milieu needs to be further investigated. [ABSTRACT FROM AUTHOR]
- Published
- 2018
- Full Text
- View/download PDF
10. Rationale and study design of the prospective, longitudinal, observational cohort study "rISk strAtification in endstage renal disease" (ISAR) study.
- Author
-
Schmaderer, Christoph, Susanne Tholen, Anna-Lena Hasenau, Hauser, Christine, Yana Suttmann, Wassertheurer, Siegfried, Mayer, Christopher C., Bauer, Axel, Rizas, Kostantinos D., Kemmner, Stephan, Kotliar, Konstantin, Haller, Bernhard, Mann, Johannes, Renders, Lutz, Heemann, Uwe, and Baumann, Marcus
- Subjects
CARDIOVASCULAR diseases risk factors ,KIDNEY diseases ,PHENOTYPES ,ELECTROCARDIOGRAPHY ,COHORT analysis ,AUTONOMIC conditioning - Abstract
Background: The ISAR study is a prospective, longitudinal, observational cohort study to improve the cardiovascular risk stratification in endstage renal disease (ESRD). The major goal is to characterize the cardiovascular phenotype of the study subjects, namely alterations in micro- and macrocirculation and to determine autonomic function. Methods/design: We intend to recruit 500 prevalent dialysis patients in 17 centers in Munich and the surrounding area. Baseline examinations include: (1) biochemistry, (2) 24-h Holter Electrocardiography (ECG) recordings, (3) 24-h ambulatory blood pressure measurement (ABPM), (4) 24 h pulse wave analysis (PWA) and pulse wave velocity (PWV), (5) retinal vessel analysis (RVA) and (6) neurocognitive testing. After 24 months biochemistry and determination of single PWA, single PWV and neurocognitive testing are repeated. Patients will be followed up to 6 years for (1) hospitalizations, (2) cardiovascular and (3) non-cardiovascular events and (4) cardiovascular and (5) all-cause mortality. Discussion/conclusion: We aim to create a complex dataset to answer questions about the insufficiently understood pathophysiology leading to excessively high cardiovascular and non-cardiovascular mortality in dialysis patients. Finally we hope to improve cardiovascular risk stratification in comparison to the use of classical and non-classical (dialysis-associated) risk factors and other models of risk stratification in ESRD patients by building a multivariable Cox-Regression model using a combination of the parameters measured in the study. [ABSTRACT FROM AUTHOR]
- Published
- 2016
- Full Text
- View/download PDF
11. Rationale and study design of the prospective, longitudinal, observational cohort study 'rISk strAtification in end-stage renal disease' (ISAR) study
- Author
-
Schmaderer, Christoph, Tholen, Susanne, Hasenau, Anna-Lena, Hauser, Christine, Suttmann, Yana, Wassertheurer, Siegfried, Mayer, Christopher C., Bauer, Axel, Rizas, Kostantinos D., Kemmner, Stephan, Kotliar, Konstantin, Haller, Bernhard, Mann, Johannes, Renders, Lutz, Heemann, Uwe, and Baumann, Marcus
- Subjects
Ambulatory blood pressure monitoring (ABPM) ,Lung Diseases ,Pulse wave velocity (PWV) ,retinal vessel analysis (RVA) ,Gastrointestinal Diseases ,Neuropsychological Tests ,Pulse Wave Analysis ,Infections ,Risk Assessment ,ISAR ,Study Protocol ,Electrocardiography ,Renal Dialysis ,Cause of Death ,Neoplasms ,Humans ,Longitudinal Studies ,Prospective Studies ,Risk stratification ,Pulse wave analysis (PWA) ,Retinal Vessels ,End stage renal disease ,Hospitalization ,Phenotype ,Cardiovascular Diseases ,Research Design ,Nephrology ,Hemodialysis ,Kidney Failure, Chronic ,Wounds and Injuries ,Montreal Cognitive Assessment (MoCA) ,Dialysis - Abstract
Background The ISAR study is a prospective, longitudinal, observational cohort study to improve the cardiovascular risk stratification in endstage renal disease (ESRD). The major goal is to characterize the cardiovascular phenotype of the study subjects, namely alterations in micro- and macrocirculation and to determine autonomic function. Methods/design We intend to recruit 500 prevalent dialysis patients in 17 centers in Munich and the surrounding area. Baseline examinations include: (1) biochemistry, (2) 24-h Holter Electrocardiography (ECG) recordings, (3) 24-h ambulatory blood pressure measurement (ABPM), (4) 24 h pulse wave analysis (PWA) and pulse wave velocity (PWV), (5) retinal vessel analysis (RVA) and (6) neurocognitive testing. After 24 months biochemistry and determination of single PWA, single PWV and neurocognitive testing are repeated. Patients will be followed up to 6 years for (1) hospitalizations, (2) cardiovascular and (3) non-cardiovascular events and (4) cardiovascular and (5) all-cause mortality. Discussion/conclusion We aim to create a complex dataset to answer questions about the insufficiently understood pathophysiology leading to excessively high cardiovascular and non-cardiovascular mortality in dialysis patients. Finally we hope to improve cardiovascular risk stratification in comparison to the use of classical and non-classical (dialysis-associated) risk factors and other models of risk stratification in ESRD patients by building a multivariable Cox-Regression model using a combination of the parameters measured in the study. Clinical trials identifier ClinicalTrials.gov NCT01152892 (June 28, 2010)
- Full Text
- View/download PDF
12. Rationale and study design of the prospective, longitudinal, observational cohort study "rISk strAtification in end-stage renal disease" (ISAR) study.
- Author
-
Schmaderer, Christoph, Tholen, Susanne, Hasenau, Anna-Lena, Hauser, Christine, Suttmann, Yana, Wassertheurer, Siegfried, Mayer, Christopher C, Bauer, Axel, Rizas, Kostantinos D, Kemmner, Stephan, Kotliar, Konstantin, Haller, Bernhard, Mann, Johannes, Renders, Lutz, Heemann, Uwe, and Baumann, Marcus
- Subjects
CARDIOVASCULAR disease related mortality ,TREATMENT of chronic kidney failure ,CHRONIC kidney failure complications ,CARDIOVASCULAR diseases ,CARDIOVASCULAR disease diagnosis ,CHRONIC kidney failure ,CAUSES of death ,ELECTROCARDIOGRAPHY ,EXPERIMENTAL design ,GASTROINTESTINAL diseases ,HEMODIALYSIS ,HOSPITAL care ,INFECTION ,LONGITUDINAL method ,LUNG diseases ,NEUROPSYCHOLOGICAL tests ,RETINA ,RISK assessment ,TUMORS ,WOUNDS & injuries ,PHENOTYPES ,DISEASE complications - Abstract
Background: The ISAR study is a prospective, longitudinal, observational cohort study to improve the cardiovascular risk stratification in endstage renal disease (ESRD). The major goal is to characterize the cardiovascular phenotype of the study subjects, namely alterations in micro- and macrocirculation and to determine autonomic function.Methods/design: We intend to recruit 500 prevalent dialysis patients in 17 centers in Munich and the surrounding area. Baseline examinations include: (1) biochemistry, (2) 24-h Holter Electrocardiography (ECG) recordings, (3) 24-h ambulatory blood pressure measurement (ABPM), (4) 24 h pulse wave analysis (PWA) and pulse wave velocity (PWV), (5) retinal vessel analysis (RVA) and (6) neurocognitive testing. After 24 months biochemistry and determination of single PWA, single PWV and neurocognitive testing are repeated. Patients will be followed up to 6 years for (1) hospitalizations, (2) cardiovascular and (3) non-cardiovascular events and (4) cardiovascular and (5) all-cause mortality.Discussion/conclusion: We aim to create a complex dataset to answer questions about the insufficiently understood pathophysiology leading to excessively high cardiovascular and non-cardiovascular mortality in dialysis patients. Finally we hope to improve cardiovascular risk stratification in comparison to the use of classical and non-classical (dialysis-associated) risk factors and other models of risk stratification in ESRD patients by building a multivariable Cox-Regression model using a combination of the parameters measured in the study.Clinical Trials Identifier: ClinicalTrials.gov NCT01152892 (June 28, 2010). [ABSTRACT FROM AUTHOR]- Published
- 2016
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.